Merck & Co., Inc. (MRK) — closed signal from December 14, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 14, 2026.
Predicted vs. what happened
What happened
Reached its target in 24 days.
The thesis — published December 14, 2025
Merck looks like a short-term buying opportunity, not a long-term rethink. A bigger $0.85 dividend in January and news about the growing women's healthcare market have pushed attention higher. Because market enthusiasm is stronger than Merck's business strength, treat this as a short swing trade: buy near support, take profits on rallies, and cut quickly if $100 fails.
Primary drivers
- Higher dividend may attract income-focused buyers soon
- Price has been pushed down enough to make a quick rebound likely
- Pharma is seen as safer when markets get rough, helping demand
- Big gap between hype and business strength means take profits quickly
How it played out
MRK: target reached in 24 days
Lyra published MRK at $100.30 on 2025-12-14 as a short-term setup with 10% expected growth. The thesis pointed to a higher dividend, a price pushed down enough for a quick rebound, safer pharma demand when markets got rough, and a gap between hype and business strength that made quick profit-taking part of the plan.
Inside the window, MRK reached the $110.33 target in 24 days. It kept rising to a $125.14 peak on 2026-02-25, a 24.8% gain from publication. The signal ended at $115.61 on 2026-03-14, still above the target. The published thesis played out.
What happened during the window
On 2026-02-03, MarketWatch reported that Merck had fourth-quarter 2025 revenue of $16.4 billion, up 5%, and adjusted earnings per share of $2.04. It also reported 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.